Core Viewpoint - BaiO Saite's stock price increased by 8.15% with a trading volume of 211 million yuan and a market capitalization of 34.639 billion yuan [1] Group 1: Company Overview - BaiO Saite (Beijing) Pharmaceutical Technology Co., Ltd. was established on November 13, 2009, and is listed on December 10, 2025 [7] - The company primarily engages in drug development and preclinical research, operating through five divisions: gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development [7] - The company is located in the Daxing District of Beijing, within the Zhongguancun Science Park [7] Group 2: Business Segments - The gene editing services division offers customized gene editing services based on animals and cells [7] - The preclinical pharmacology and efficacy evaluation division provides services for drug efficacy and toxicity assessment [7] - The model animal sales division breeds and sells both external and internal model animals and licenses several model animals to clients [7] - The antibody development division identifies potential candidate antibodies for drug development and collaborates with partners [7] - The innovative drug development division focuses on developing new drugs, particularly for oncology and autoimmune diseases [7] Group 3: Financial Performance - As of the 2024 annual report, overseas revenue accounted for 67.94% of total revenue, benefiting from the depreciation of the RMB [3] - The stock has seen a net inflow of 2.1842 million yuan from major investors today, with a total net inflow of -889 million yuan over the past three days [4][5] Group 4: Market Position - BaiO Saite is categorized under the pharmaceutical and biotechnology industry, specifically in medical services and medical research outsourcing [7] - The company is part of several concept sectors, including small and mid-cap stocks, pre-profit growth, AI applications, and securities lending [7]
百奥赛图涨8.15%，成交额2.11亿元，近5日主力净流入-975.39万